Nurr1-Based Therapies for Parkinson's Disease

CNS Neuroscience and Therapeutics

Volumn 22, Issue 5, 2016, Pages 351-359

  Dong, Jie ^a   Li, Song ^a   Mo, Jing Lin ^a   Cai, Huai Bin ^b   Le, Wei Dong ^a,c  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Inflammation; Neuroprotection; Nurr1; Parkinson's disease; Treatment

Indexed keywords

1,1 BIS(3' INDOLYL) 1 (AROMATIC)METHANE DERIVATIVE; AMODIAQUINE; CHLOROQUINE; DOPAMINE RECEPTOR STIMULATING AGENT; GINKGO BILOBA EXTRACT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ISOXAZOLOPYRIDINONE 7E; MEMANTINE; MERCAPTOPURINE; MORACENIN D; NATURAL PRODUCT; NEUROPROTECTIVE AGENT; NEURTURIN; NUCLEAR RECEPTOR RELATED FACTOR 1; PARVOVIRUS VECTOR; PRAMIPEXOLE; RADICICOL; RETINOIC ACID; SA 00025; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IMMEDIATE EARLY GENE; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; GENETICS; METABOLISM; PRECLINICAL STUDY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; PARKINSON DISEASE;

EID: 84961595310     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12536     Document Type: Article

References (120)

1. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-393.
2. Le WD, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 2009;15:28-35.
3. Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 2015;31:140-149.
4. Nolan YM, Sullivan AM, Toulouse A. Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol Med 2013;19:187-196.
5. Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 2013;532:18-23.
6. Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. Mov Disord 2013;28:24-30.
7. Goetz CG, Pal G. Initial management of Parkinson's disease. BMJ 2014;349:g6258.
8. Dong J, Cui Y, Li S, Le W. Current pharmaceutical treatments and alternative therapies of Parkinson's diseases. Curr Neuropharmacol 2015. [Epub ahead of print].
9. Giguere V. Orphan nuclear receptors: from gene to function. Endocr Rev 1999;20:689-725.
10. Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 2005;77:128-138.
11. Zetterström RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997;276:248-250.
12. Chu Y, Kompoliti K, Cochran EJ, Mufson EJ, Kordower JH. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 2002;450:203-214.
13. Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007;25:134-149.
14. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 2006;494:495-514.
15. Moran LB, Croisier E, Duke DC, et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol 2007;113:253-263.
16. Le W, Pan T, Huang M, et al. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci 2008;273:29-33.
17. Decressac M, Volakakis N, Björklund A, Perlmann T. NURR1 in Parkinson disease-from pathogenesis to therapeutic potential. Nat Rev Neurol 2013;9:629-636.
18. Le W, Conneely OM, He Y, Jankovic J, Appel SH. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem 1999;73:2218-2221.
19. Le W, Conneely OM, Zou L, et al. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol 1999;159:451-458.
20. Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 2005;191:154-162.
21. Kadkhodaei B, Alvarsson A, Schintu N, et al. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl Acad Sci USA 2013;110:2360-2365.
22. Heng X, Jin G, Zhang X, et al. Nurr1 regulates Top IIβ and functions in axon genesis of mesencephalic dopaminergic neurons. Mol Neurodegener 2012;7:4.
23. Eells JB, Misler JA, Nikodem VM. Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice. Brain Res Bull 2006;70:186-195.
24. Jacobs FMJ, van der Linden AJ, Wang Y, et al. Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons. Development 2009;136:2363-2373.
25. Gil M, McKinney C, Lee MK, Eells JB, Phyillaier M, Nikodem VM. Regulation of GTP cyclohydrolase I expression by orphan receptor Nurr1 in cell culture and in vivo. J Neurochem 2007;101:142-150.
26. Luo Y, Henricksen LA, Giuliano RE, Prifti L, Callahan LM, Federoff HJ. VIP is a transcriptional target of Nurr1 in dopaminergic cells. Exp Neurol 2007;203:221-232.
27. Castelo-Branco G, Wagner J, Rodriguez FJ, et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci USA 2003;100:12747-12752.
28. Joksimovic M, Yun BA, Kittappa R, et al. Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. Nat Neurosci 2009;12:125-131.
29. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA 1998;95:4013-4018.
30. Lin X, Parisiadou L, Sgobio C, et al. Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci 2012;32:9248-9264.
31. Wallén Aa, Castro DS, Zetterström RH, et al. Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem. Mol Cell Neurosci 2001;18:649-663.
32. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 2012;4:163ra156.
33. Saijo K, Winner B, Carson CT, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009;137:47-59.
34. Maxwell Ma, Muscat GEO. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal 2006;4:002.
35. Ichinose H, Ohye T, Suzuki T, et al. Molecular cloning of the human Nurr1 gene: characterization of the human gene and cDNAs. Gene 1999;230:233-239.
36. Paulsen RF, Granas K, Johnsen H, Rolseth V, Sterri S. Three related brain nuclear receptors, NGFI-B, Nurr1, and NOR-1, as transcriptional activators. J Mol Neurosci 1995;6:249-255.
37. Maira M, Martens C, Philips A, Drouin J. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 1999;19:7549-7557.
38. Perlmann T, Jansson L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev 1995;9:769-782.
39. Wang Z, Benoit G, Liu J, et al. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 2003;423:555-560.
40. Maira M, Martens C, Batsché E, Gauthier Y, Drouin J. Dimer-specific potentiation of NGFI-B (Nur77) transcriptional activity by the protein kinase A pathway and AF-1-dependent coactivator recruitment. Mol Cell Biol 2003;23:763-776.
41. Codina A, Benoit G, Gooch JT, Neuhaus D, Perlmann T, Schwabe JWR. Identification of a novel Co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting. J Biol Chem 2004;279:53338-53345.
42. Volakakis N, Malewicz M, Kadkhodai B, Perlmann T, Benoit G. Characterization of the Nurr1 ligand-binding domain co-activator interaction surface. J Mol Endocrinol 2006;37:317-326.
43. Kim CH, Han BS, Moon J, et al. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease. Proc Natl Acad Sci 2015;112:8756-8761.
44. Zhan Y, Du X, Chen H, et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat Chem Biol 2008;4:548-556.
45. Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K, Safe S. Activation of Nur77 by selected 1, 1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J Biol Chem 2005;280:24903-24914.
46. Ordentlich P, Yan Y, Zhou S, Heyman RA. Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1. J Biol Chem 2003;278:24791-24799.
47. Wansa KDSA, Harris JM, Yan G, Ordentlich P, Muscat GEO. The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. J Biol Chem 2003;278:24776-24790.
48. Dubois C, Hengerer B, Mattes H. Identification of a potent agonist of the orphan nuclear receptor Nurr1. ChemMedChem 2006;1:955-958.
49. Hedrick E, Lee SO, Kim G, et al. Nuclear receptor 4A1 (NR4A1) as a drug target for renal cell adenocarcinoma. PLoS ONE 2015;10:e0128308.
50. Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1, 1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther 2008;7:3825-3833.
51. Yoon K, Lee SO, Cho SD, Kim K, Khan S, Safe S. Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors. Carcinogenesis 2011;32:836-842.
52. Li X, Lee SO, Safe S. Structure-dependent activation of NR4A2 (Nurr1) by 1, 1-bis(3'-indolyl)-1-(aromatic)methane analogs in pancreatic cancer cells. Biochem Pharmacol 2012;83:1445-1455.
53. De Miranda BR, Popichak KA, Hammond SL, Miller JA, Safe S, Tjalkens RB. Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease. Toxicol Sci 2015;143:360-373.
54. De Miranda BR, Popichak KA, Hammond SL, et al. The Nurr1 activator 1, 1-Bis(3'-Indolyl)-1-(p-Chlorophenyl) methane blocks inflammatory gene expression in BV-2 microglial cells by inhibiting nuclear factor κB. Mol Pharmacol 2015;87:1021-1034.
55. Hammond SL, Safe S, Tjalkens RB. A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro. Neurosci Lett 2015;607:83-89.
56. Montarolo F, Raffaele C, Perga S, et al. Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice. PLoS ONE 2014;9:e108791.
57. Hintermann S, Chiesi M, von Krosigk U, Mathé D, Felber R, Hengerer B. Identification of a series of highly potent activators of the Nurr1 signaling pathway. Bioorg Med Chem Lett 2007;17:193-196.
58. Zhang Z, Li X, Xie W, et al. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets 2012;11:768-773.
59. Smith GA, Rocha EM, Rooney T, et al. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS ONE 2015;10:e0121072.
60. Qiao S, Tao S, Rojo de la Vega M, et al. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy 2013;9:2087-2102.
61. Eells JB, Wilcots J, Sisk S, Guo-Ross SX. NR4A gene expression is dynamically regulated in the ventral tegmental area dopamine neurons and is related to expression of dopamine neurotransmission genes. J Mol Neurosci 2012;46:545-553.
62. McMorrow JP, Murphy EP. Inflammation: a role for NR4A orphan nuclear receptors? Biochem Soc Trans 2011;39:688-693.
63. Wei X, Gao H, Zou J, et al. Contra-directional coupling of Nur77 and Nurr1 in Neurodegeneration: a novel mechanism for memantine-induced anti-inflammation and anti-mitochondrial impairment. Mol Neurobiol 2015. [Epub ahead of print].
64. Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett 2005;377:106-109.
65. Ham A, Lee HJ, Hong SS, Lee D, Mar W. Moracenin D from Mori Cortex radicis protects SH-SY5Y cells against dopamine-induced cell death by regulating nurr1 and α-synuclein expression. Phytother Res 2012;26:620-624.
66. Rojas P, Ruiz-Sánchez E, Rojas C, Ogren SO. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinsonism in mice. Neuroscience 2012;223:246-257.
67. Pan T, Xie W, Jankovic J, Le WD. Radicicol induces heat shock protein expression and neuroprotection against rotenone-mediated apoptosis in SH-SY5Y cells. Mov Disord 2005;20:S86-S86.
68. Li M, Yang MH, Liu Y, Luo XD, Chen JZ, Shi HJ. Analysis of clinical evaluation of response to treatment of Parkinson's disease with integrated Chinese and Western medicine therapy. Chin J Integr Med 2015;21:17-21.
69. Esteves M, Cristóvão AC, Saraiva T, et al. Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease. Front Aging Neurosci 2015;7:20.
70. Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson's disease. Expert Opin Investig Drugs 2014;23:387-410.
71. Zhang LM, Sun CC, Mo MS, et al. Dopamine agonists exert Nurr1-inducing effect in peripheral blood mononuclear cells of patients with Parkinson's disease. Chin Med J. (Engl) 2015;128:1755-1760.
72. Kiss B, Tóth K, Sarang Z, Garabuczi É, Szondy Z. Retinoids induce Nur77-dependent apoptosis in mouse thymocytes. Biochim Biophys Acta 2015;1853:660-670.
73. Li L, Liu Y, Chen H, et al. Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. Nat Chem Biol 2015;11:339-346.
74. Gervais J, Soghomonian JJ, Richard D, Rouillard C. Dopamine and serotonin interactions in the modulation of the expression of the immediate-early transcription factor, nerve growth factor-inducible B, in the striatum. Neuroscience 1999;91:1045-1054.
75. ®) in dementia with behavioural and psychological symptoms: a systematic review. World J Biol Psychiatry 2015;1-12.
76. Chen X, Hong Y, Zheng P. Efficacy and safety of extract of ginkgo biloba as an adjunct therapy in chronic schizophrenia: a systematic review of randomized, double-blind, placebo-controlled Studies with meta-analysis. Psychiatry Res 2015;228:121-127.
77. Yang MH, Wang HM, Liu Y. Effect of Bushen Huoxue Decoction on the orphan receptor and tyrosine hydroxylase in the brain of rats with Parkinson's disease. Chin J Integr Med 2011;17:43-47.
78. Katsuki H, Kurimoto E, Takemori S, et al. Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling. J Neurochem 2009;110:707-718.
79. Oh S, Chang M, Song J, et al. Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease. EMBO Mol Med 2015;7:510-525.
80. Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80:1698-1701.
81. Ji R, Sanchez CM, Chou CL, Chen XB, Woodward DF, Regan JW. Prostanoid EP1 receptors mediate up-regulation of the orphan nuclear receptor Nurr1 by cAMP-independent activation of protein kinase A, CREB and NF-κB. Br J Pharmacol 2012;166:1033-1046.
82. Bousquet M, Gue K, Emond V, et al. Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease. J Lipid Res 2011;52:263-271.
83. Kovalovsky D, Refojo D, Liberman AC, et al. Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 2002;16:1638-1651.
84. Zhao D, Desai S, Zeng H. VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: role in VEGF-induced angiogenesis. Int J Cancer 2011;128:2602-2612.
85. Bandoh S, Tsukada T, Maruyama K, Ohkura N, Yamaguchi K. Mechanical agitation induces gene expression of (NOR)-1 and its closely related orphan nuclear receptors in leukemic cell lines. Leukemia 1997;11:1453-1458.
86. Tokuoka H, Hatanaka T, Metzger D, Ichinose H. Nurr1 expression is regulated by voltage-dependent calcium channels and calcineurin in cultured hippocampal neurons. Neurosci Lett 2014;559:50-55.
87. Friling S, Bergsland M, Kjellander S. Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease. BMC Neurosci 2009;10:146.
88. Lei Z, Jiang Y, Li T, Zhu J, Zeng S. Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease. J Neuropathol Exp Neurol 2011;70:736-747.
89. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002;35:605-623.
90. Chang YL, Chen SJ, Kao CL, et al. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology. Cell Transplant 2012;21:313-332.
91. McFarland K, Spalding TA, Hubbard D, Ma J-N, Olsson R, Burstein ES. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chem Neurosci 2013;4:1430-1438.
92. Volakakis N, Tiklova K, Decressac M, et al. Nurr1 and retinoid X receptor ligands stimulate ret signaling in dopamine neurons and can alleviate-synuclein disrupted gene expression. J Neurosci 2015;35:14370-14385.
93. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-424.
94. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-466.
95. Sathiya S, Ranju V, Kalaivani P, et al. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. Neuropharmacology 2013;73:98-110.
96. Naveilhan P, Neveu I, Wion D, Brachet P. 1, 25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. NeuroReport 1996;7:2171-2175.
97. Sapkota K, Kim S, Kim MK, Kim SJ. A detoxified extract of Rhus verniciflua Stokes upregulated the expression of BDNF and GDNF in the rat brain and the human dopaminergic cell line SH-SY5Y. Biosci Biotechnol Biochem 2010;74:1997-2004.
98. Ohta K, Fujinami A, Kuno S, et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 2004;71:162-168.
99. Li X, Tai H-H. Activation of thromboxane A2 receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. Carcinogenesis 2009;30:1606-1613.
100. Barneda-Zahonero B, Servitja JM, Badiola N, et al. Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival. J Biol Chem 2012;287:11351-11362.
101. L'Episcopo F, Tirolo C, Testa N, et al. Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease. Stem Cells 2014;32:2147-2163.
102. Rajalin A-M, Aarnisalo P. Cross-talk between NR4A orphan nuclear receptors and β-catenin signaling pathway in osteoblasts. Arch Biochem Biophys 2011;509:44-51.
103. Berthon A, Drelon C, Ragazzon B, et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet 2014;23:889-905.
104. L'Episcopo F, Tirolo C, Testa N, et al. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 2011;41:508-527.
105. Wei L, Sun C, Lei M, et al. Activation of Wnt/β-catenin Pathway by Exogenous Wnt1 Protects SH-SY5Y Cells Against 6-Hydroxydopamine Toxicity. J Mol Neurosci 2013;49:105-115.
106. Devine MJ. Proteasomal inhibition as a treatment strategy for Parkinson's disease: the impact of α-synuclein on Nurr1. J Neurosci 2012;32:16071-16073.
107. Yang D, Li T, Wang Y, et al. miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression. J Cell Sci 2012;125:1673-1682.
108. Myöhänen TT, Hannula MJ, Van Elzen R, et al. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br J Pharmacol 2012;166:1097-1113.
109. Fagerqvist T, Lindström V, Nordström E, et al. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation. J Neurochem 2013;126:131-144.
110. Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2013;73:155-169.
111. Gascon E, Gao FB. Cause or Effect: misregulation of microRNA Pathways in Neurodegeneration. Front Neurosci 2012;6:48.
112. Harraz MM, Dawson TM, Dawson VL. MicroRNAs in Parkinson's disease. J Chem Neuroanat 2011;42:127-130.
113. Li QJ, Tang YM, Liu J, et al. Treatment of Parkinson disease with C17.2 neural stem cells overexpressing NURR1 with a recombined republic-deficit adenovirus containing the NURR1 gene. Synapse 2007;61:971-977.
114. Shim JW, Park CH, Bae YC, et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem Cells 2007;25:1252-1262.
115. Park CH, Kang JS, Shin YH, et al. Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons. FASEB J 2006;20:2553-2555.
116. Tan X, Zhang L, Qin J, et al. Transplantation of neural stem cells co-transfected with Nurr1 and Brn4 for treatment of Parkinsonian rats. Int J Dev Neurosci 2013;31:82-87.
117. Lee HS, Bae EJ, Yi SH, et al. Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival. Stem Cells 2010;28:501-512.
118. Ko TL, Fu YY, Shih YH, et al. A high efficiency induction of dopaminergic cells from human umbilical mesenchymal stem cells for the treatment of hemiparkinsonian rats. Cell Transplant 2014;24:2251-2262.
119. Gross RE, Watts RL, Hauser R, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2011;10:509-519.
120. Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol 2010;30:1535-1541.